377 related articles for article (PubMed ID: 10721486)
1. Defining a novel domain of staphylococcal toxic shock syndrome toxin-1 critical for major histocompatibility complex class II binding, superantigenic activity, and lethality.
Kum WW; Laupland KB; Chow AW
Can J Microbiol; 2000 Feb; 46(2):171-9. PubMed ID: 10721486
[TBL] [Abstract][Full Text] [Related]
2. Identification from a phage display library of peptides that bind to toxic shock syndrome toxin-1 and that inhibit its binding to major histocompatibility complex (MHC) class II molecules.
Sato A; Ida N; Fukuyama M; Miwa K; Kazami J; Nakamura H
Biochemistry; 1996 Aug; 35(32):10441-7. PubMed ID: 8756700
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of staphylococcal enterotoxin A-induced superantigenic and lethal activities by a monoclonal antibody to toxic shock syndrome toxin-1.
Kum WW; Chow AW
J Infect Dis; 2001 Jun; 183(12):1739-48. PubMed ID: 11372026
[TBL] [Abstract][Full Text] [Related]
4. Identification of binding domains on the superantigen, toxic shock syndrome-1, for class II MHC molecules.
Soos JM; Russell JK; Jarpe MA; Pontzer CH; Johnson HM
Biochem Biophys Res Commun; 1993 Mar; 191(3):1211-7. PubMed ID: 8466498
[TBL] [Abstract][Full Text] [Related]
5. Separation of function between the domains of toxic shock syndrome toxin-1.
Wahlsten JL; Ramakrishnan S
J Immunol; 1998 Jan; 160(2):854-9. PubMed ID: 9551921
[TBL] [Abstract][Full Text] [Related]
6. Carboxy-terminal residues of major histocompatibility complex class II-associated peptides control the presentation of the bacterial superantigen toxic shock syndrome toxin-1 to T cells.
Wen R; Broussard DR; Surman S; Hogg TL; Blackman MA; Woodland DL
Eur J Immunol; 1997 Mar; 27(3):772-81. PubMed ID: 9079821
[TBL] [Abstract][Full Text] [Related]
7. Binding of toxic shock syndrome toxin-1 to murine major histocompatibility complex class II molecules.
Scholl PR; Sekaly RP; Diez A; Glimcher LH; Geha RS
Eur J Immunol; 1990 Sep; 20(9):1911-6. PubMed ID: 2209697
[TBL] [Abstract][Full Text] [Related]
8. Characterization of T cell receptors engineered for high affinity against toxic shock syndrome toxin-1.
Buonpane RA; Moza B; Sundberg EJ; Kranz DM
J Mol Biol; 2005 Oct; 353(2):308-21. PubMed ID: 16171815
[TBL] [Abstract][Full Text] [Related]
9. Superantigen antagonist blocks Th1 cytokine gene induction and lethal shock.
Arad G; Hillman D; Levy R; Kaempfer R
J Leukoc Biol; 2001 Jun; 69(6):921-7. PubMed ID: 11404377
[TBL] [Abstract][Full Text] [Related]
10. Major histocompatibility complex class II-associated peptides determine the binding of the superantigen toxic shock syndrome toxin-1.
von Bonin A; Ehrlich S; Malcherek G; Fleischer B
Eur J Immunol; 1995 Oct; 25(10):2894-8. PubMed ID: 7589089
[TBL] [Abstract][Full Text] [Related]
11. Structural basis of superantigen action inferred from crystal structure of toxic-shock syndrome toxin-1.
Acharya KR; Passalacqua EF; Jones EY; Harlos K; Stuart DI; Brehm RD; Tranter HS
Nature; 1994 Jan; 367(6458):94-7. PubMed ID: 8107781
[TBL] [Abstract][Full Text] [Related]
12. Activation of murine T cells by toxic shock syndrome toxin-1. The toxin-binding structures expressed on murine accessory cells are MHC class II molecules.
Uchiyama T; Tadakuma T; Imanishi K; Araake M; Saito S; Yan XJ; Fujikawa H; Igarashi H; Yamaura N
J Immunol; 1989 Nov; 143(10):3175-82. PubMed ID: 2509554
[TBL] [Abstract][Full Text] [Related]
13. A mutation at glycine residue 31 of toxic shock syndrome toxin-1 defines a functional site critical for major histocompatibility complex class II binding and superantigenic activity.
Kum WW; Wood JA; Chow AW
J Infect Dis; 1996 Dec; 174(6):1261-70. PubMed ID: 8940217
[TBL] [Abstract][Full Text] [Related]
14. The alpha 1 domain of the HLA-DR molecule is essential for high-affinity binding of the toxic shock syndrome toxin-1.
Karp DR; Teletski CL; Scholl P; Geha R; Long EO
Nature; 1990 Aug; 346(6283):474-6. PubMed ID: 2377209
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of staphylococcal enterotoxin B-induced lymphocyte proliferation and tumor necrosis factor alpha secretion by MAb5, an anti-toxic shock syndrome toxin 1 monoclonal antibody.
Pang LT; Kum WW; Chow AW
Infect Immun; 2000 Jun; 68(6):3261-8. PubMed ID: 10816471
[TBL] [Abstract][Full Text] [Related]
16. Defense against biologic warfare with superantigen toxins.
Kaempfer R; Arad G; Levy R; Hillman D
Isr Med Assoc J; 2002 Jul; 4(7):520-3. PubMed ID: 12120463
[TBL] [Abstract][Full Text] [Related]
17. Modeling of receptor mimics that inhibit superantigen pathogenesis.
Möllhoff M; Zanden HB; Shiflett PR; Gupta G
J Mol Recognit; 2005; 18(1):73-83. PubMed ID: 15459942
[TBL] [Abstract][Full Text] [Related]
18. Functional analysis of the TCR binding domain of toxic shock syndrome toxin-1 predicts further diversity in MHC class II/superantigen/TCR ternary complexes.
McCormick JK; Tripp TJ; Llera AS; Sundberg EJ; Dinges MM; Mariuzza RA; Schlievert PM
J Immunol; 2003 Aug; 171(3):1385-92. PubMed ID: 12874229
[TBL] [Abstract][Full Text] [Related]
19. Dissection of the function of HLA class II and costimulation in B cell-mediated and toxic shock syndrome toxin-1-induced T cell proliferation.
Dennig D; O'Reilly RJ
J Immunol; 1993 Jun; 150(12):5231-40. PubMed ID: 7685791
[TBL] [Abstract][Full Text] [Related]
20. Synergistic effect between CD40 and class II signals overcome the requirement for class II dimerization in superantigen-induced cytokine gene expression.
Mehindate K; al-Daccak R; Damdoumi F; Mourad W
Eur J Immunol; 1996 Sep; 26(9):2075-80. PubMed ID: 8814249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
